

GLAXOSMITHKLINE PLC  
Form 6-K  
April 19, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 19 April 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley  
 b) Position/status Chief Executive Officer

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
	ISIN: GB0009252882
	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
b) Nature of the transaction	Price(s) Volume(s)
	£16.47 82.730 (personal contribution)
	£16.47 204.873 (personal contribution)
	£16.47 223.059 (personal contribution)
	£16.47 82.730 (personal contribution)
	£16.47 204.858 (personal contribution)

c) Price(s) and volume(s)

£16.47 223.045 (personal contribution)

£16.47 82.730 (matching shares)

£16.47 204.873 (matching shares)

£16.47 223.059 (matching shares)

£16.47 82.730 (matching shares)

£16.47 204.858 (matching shares)

£16.47 223.045 (matching shares)

Aggregated information

d) 2,042.590

Aggregated volume Price £16.47

e) Date of the transaction 2017-04-18

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor

b) Position/status President, Global Manufacturing & Supply

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)

£16.47 60.585 (personal contribution)

£16.47 139.194 (personal contribution)

£16.47 116.145 (personal contribution)  
 £16.47 60.585 (personal contribution)  
 £16.47 116.131 (personal contribution)  
 £16.47 60.585 (matching shares)  
 £16.47 139.194 (matching shares)  
 £16.47 116.145 (matching shares)  
 £16.47 60.585 (matching shares)  
 £16.47 116.131 (personal contribution)

Aggregated information  
 d) Aggregated volume Price

985.280  
 £16.47

e) Date of the transaction 2017-04-18

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne  
 b) Position/status President, Global Vaccines  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,  
 auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;  
 (ii) each type of transaction; (iii) each date; and (iv) each place where  
 transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each  
 ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882  
 Increase in notional interest in Ordinary  
 Shares following the re-investment of  
 dividends paid to shareholders on 13  
 April 2017 on Ordinary Shares held in  
 the Company's 2009 Deferred Annual  
 Bonus Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £16.47 195.213 (personal contribution)

£16.47 195.199 (personal contribution)

£16.47 195.213 (matching shares)

£16.47 195.199 (matching shares)

Aggregated information

d) Aggregated volume Price 780.824  
£16.47

e) Date of the transaction 2017-04-18

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans  
b) Position/status Chief Financial Officer  
c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882  
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)  
£16.47 115.556 (personal contribution)

£16.47 270.551 (personal contribution)

£16.47 202.642 (personal contribution)

£16.47 115.540 (personal contribution)

£16.47 270.537 (personal contribution)

£16.47 202.642 (personal contribution)

c) Price(s) and volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£16.47 115.556 (matching shares)  
 £16.47 270.551 (matching shares)  
 £16.47 202.642 (matching shares)  
 £16.47 115.540 (matching shares)  
 £16.47 270.537 (matching shares)  
 £16.47 202.642 (matching shares)

Aggregated information

d) Aggregated volume Price 2,354.936  
 £16.47

e) Date of the transaction 2017-04-18

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons  
 b) Position/status SVP, Global Ethics & Compliance

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,  
 auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;  
 (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)  
 has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each  
 ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882  
 Increase in notional interest in Ordinary  
 Shares following the re-investment of  
 dividends paid to shareholders on 13 April  
 2017 on Ordinary Shares held in the  
 Company's 2009 Deferred Annual Bonus  
 Plan.

Price(s) Volume(s)  
 £16.47 42.420 (personal contribution)  
 £16.47 100.034 (personal contribution)  
 £16.47 73.412 (personal contribution)  
 £16.47 42.420 (personal contribution)

c) Price(s) and volume(s)

£16.47 100.034 (personal contribution)  
 £16.47 73.398 (personal contribution)  
 £16.47 42.420 (matching shares)  
 £16.47 100.034 (matching shares)  
 £16.47 73.412 (matching shares)  
 £16.47 42.420 (matching shares)  
 £16.47 100.034 (matching shares)  
 £16.47 73.398 (matching shares)

Aggregated information  
 d) Aggregated volume Price

863.436  
 £16.47

e) Date of the transaction

2017-04-18

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Mr S A Hussain

b) Position/status

President, Global Pharmaceuticals

c) Initial notification/  
 amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,  
 auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;  
 (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)  
 has been conducted

Ordinary shares of 25 pence each  
 ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction

Increase in notional interest in Ordinary  
 Shares following the re-investment of  
 dividends paid to shareholders on 13 April  
 2017 on Ordinary Shares held in the  
 Company's 2009 Deferred Annual Bonus  
 Plan.

Price(s) Volume(s)

£16.47 199.970 (personal contribution)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£16.47 236.389 (personal contribution)  
 £16.47 202.908 (personal contribution)  
 £16.47 236.389 (personal contribution)  
 £16.47 202.894 (personal contribution)  
 £16.47 199.970 (matching shares)  
 £16.47 236.389 (matching shares)  
 £16.47 202.908 (matching shares)  
 £16.47 236.389 (matching shares)  
 £16.47 202.894 (matching shares)

Aggregated information  
 d) Aggregated volume Price

2,157.100  
 £16.47

e) Date of the transaction  
 f) Place of the transaction

2017-04-18  
 n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara  
 b) Position/status CEO, GSK Consumer Healthcare  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares ('ADSs')  
 ISIN: US37733W1053  
 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.  
 b) Nature of the transaction  
 c) Price(s) and volume(s) Price(s) Volume(s)  
 \$41.81 82.979 (personal contribution)  
 \$41.81 82.979 (matching shares)



Aggregated information	165.958
d) Aggregated volume Price	\$41.81
e) Date of the transaction	2017-04-18
f) Place of the transaction	n/a
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each (‘Ordinary Shares’)
b) Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £16.47 67.977 (personal contribution)
	£16.47 127.311 (personal contribution)
	£16.47 92.391 (personal contribution)
	£16.47 67.977 (personal contribution)
	£16.47 127.311 (personal contribution)
	£16.47 92.377 (personal contribution)
	£16.47 67.977 (matching shares)
	£16.47 127.311 (matching shares)
	£16.47 92.391 (matching shares)

£16.47 67.977 (matching shares)

£16.47 127.311 (matching shares)

£16.47 92.377 (matching shares)

Aggregated information 1,150.688  
 d) £16.47  
 Aggregated volume Price

e) Date of the transaction 2017-04-18

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, Human Resources

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,  
 auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;  
 (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)  
 has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each  
 ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary  
 Shares following the re-investment of  
 dividends paid to shareholders on 13 April  
 2017 on Ordinary Shares held in the  
 Company's 2009 Deferred Annual Bonus  
 Plan.

Price(s) Volume(s)  
 £16.47 91.499 (personal contribution)

£16.47 186.252 (personal contribution)

£16.47 139.061 (personal contribution)

£16.47 91.483 (personal contribution)

£16.47 186.252 (personal contribution)

c) Price(s) and volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£16.47 139.061 (personal contribution)  
 £16.47 91.499 (matching shares)  
 £16.47 186.252 (matching shares)  
 £16.47 139.061 (matching shares)  
 £16.47 91.483 (matching shares)  
 £16.47 186.252 (matching shares)  
 £16.47 139.061 (matching shares)

Aggregated information 1,667.216  
 d) Aggregated volume Price £16.47

e) Date of the transaction 2017-04-18  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson  
 b) Position/status President, Global Affairs  
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882  
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)  
 £16.47 62.146 (personal contribution)  
 £16.47 113.955 (personal contribution)

c) Price(s) and volume(s)

£16.47 87.545 (personal contribution)

£16.47 62.146 (matching shares)

£16.47 113.955 (matching shares)

£16.47 87.545 matching shares)

Aggregated information 527.292  
 d) Aggregated volume Price £16.47

e) Date of the transaction 2017-04-18

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D E Troy  
 b) Position/status SVP & General Counsel

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,  
 auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;  
 (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)  
 has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')

ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest in ADSs  
 following the re-investment of dividends  
 paid to shareholders on 13 April 2017 on  
 ADSs held in the Company's 2009  
 Deferred Annual Bonus Plan.

Price(s) Volume(s)  
 \$41.81 47.220 (personal contribution)

\$41.81 106.319 (personal contribution)

\$41.81 88.057 (personal contribution)

\$41.81 47.220 (personal contribution)

\$41.81 106.319 (personal contribution)

c) Price(s) and volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

\$41.81	88.044 (personal contribution)
\$41.81	47.220 (matching shares)
\$41.81	106.319 (matching shares)
\$41.81	88.057 (matching shares)
\$41.81	47.220 (matching shares)
\$41.81	106.319 (matching shares)
\$41.81	88.044 (matching shares)

Aggregated information  
d) Aggregated volume Price

966.358  
\$41.81

e) Date of the transaction 2017-04-18

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance  
b) Position/status President, R&D

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,  
auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. (i) each type of transaction; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)  
has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each  
('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882  
Increase in notional interest in Ordinary  
Shares following the re-investment of  
dividends paid to shareholders on 13 April  
2017 on Ordinary Shares held in the  
Company's 2009 Deferred Annual Bonus  
Plan.

Price(s) Volume(s)  
£16.47 134.685 (personal contribution)

£16.47 219.092 (personal contribution)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£16.47 151.043 (personal contribution)  
£16.47 134.685 (personal contribution)  
£16.47 219.092 (personal contribution)  
£16.47 151.043 (personal contribution)  
£16.47 134.685 (matching shares)  
£16.47 219.092 (matching shares)  
£16.47 151.043 (matching shares)  
£16.47 134.685 (matching shares)  
£16.47 219.092 (matching shares)  
£16.47 151.043 (matching shares)

Aggregated information 2,019.280  
d) £16.47  
Aggregated volume Price  
  
e) Date of the transaction 2017-04-18  
f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 19, 2017

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc